Mepolizumab

Extended indication	COPD
Therapeutic value	No judgement
Total cost	1,971,022,500.00

Product

Active substance	Mepolizumab
Domain	Lung diseases
Main indication	COPD
Extended indication	COPD
Proprietary name	Nucala
Manufacturer	GSK
Route of administration	Subcutaneous
Therapeutical formulation	Injection
Budgetting framework	Intermural (MSZ)
Additional remarks	Al geregistreerd voor astma.

Registration

Registration route	Centralised (EMA)
Expected Registration	2018
Orphan drug	No
Additional remarks	Indicatie-uitbreiding

Therapeutic value

Therapeutic value	No judgement
Substantiation	Wordt off-label al voorgeschreven.
Duration of treatment	Not found
Frequency of administration	1 times a month
Dosage per administration	100 mg

Expected patient volume per year

Patient volume	5,000 - 250,000 Market share is generally not included unless otherwise stated.

Patient volume

5,000 - 250,000

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost	< 15,459.00
References	Medicijnkosten.nl
Additional remarks	Meerkosten. per injectieflacon van 100mg fl € 1263,52. Komt bovenop huidige kosten.

Potential total cost per year

Total cost	1,971,022,500.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Total cost

1,971,022,500.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use	Yes
Indications off label use	Gezien lastige indicatiestelling - grote kans op off-label gebruik.

Indication extension

Indication extension	Yes
Indication extensions	Meerdere fase 3 studies

Other information

There is currently no futher information available.